Valeria Calabrese

Dr. Valeria Calabrese

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 September 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
PKParaskevi Krashia
Paraskevi Krashia
ACAlberto Cordella
Alberto Cordella
ANAnnalisa Nobili
Annalisa Nobili
LBLivia La Barbera
Livia La Barbera
MFMauro Federici
Mauro Federici
Nicola Biagio MercuriNicola Biagio Mercuri
Nicola Biagio Mercuri
Neuroinflammation is one of the hallmarks of Parkinson’s disease (PD) and may contribute to midbrain dopamine (DA) neuron degeneration. Recent studies link chronic inflammation with failure to resolve early inflammation, a process operated by specialized pro-resolving mediators, including resolvins. However, the effects of stimulating the resolution of inflammation in PD – to modulate disease progression – still remain unexplored. Here we show that rats overexpressing human α-synuclein (Syn) display altered DA neuron properties, reduced striatal DA outflow and motor deficits prior to nigral degeneration. These early alterations are coupled with microglia activation and perturbations of inflammatory and pro-resolving mediators, namely IFN-γ and resolvin D1 (RvD1). Chronic and early RvD1 administration in Syn rats prevents central and peripheral inflammation, as well as neuronal dysfunction and motor deficits. We also show that endogenous RvD1 is decreased in human patients with early-PD. Our results suggest there is an imbalance between neuroinflammatory and pro-resolving processes in PD.

4 May 2018 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
VGVeronica Ghiglieri
Veronica Ghiglieri
VCValeria Calabrese
Valeria Calabrese
PCPaolo Calabresi
Paolo Calabresi
Over the last two decades, many experimental and clinical studies have provided solid evidence that alpha-synuclein (α-syn), a small, natively unfolded protein, is closely related to Parkinson’s disease (PD) pathology. To provide an overview on the different roles of this protein, here we propose a synopsis of seminal and recent studies that explored the many aspects of α-syn. Ranging from the physiological functions to its neurodegenerative potential, the relationship with the possible pathogenesis of PD will be discussed. Close attention will be paid on early cellular and molecular alterations associated with the presence of α-syn aggregates.

29 March 2019 in Brain
Verified
Journal Article
Closed access
VDValentina Durante
Valentina Durante
AIAntonio de Iure
Antonio de Iure
VLVittorio Loffredo
Vittorio Loffredo
NVNishant Vaikath
Nishant Vaikath
MRMaria De Risi
Maria De Risi
PCPaolo Calabresi
Paolo Calabresi
Parkinson's disease is a progressive neurodegenerative disorder characterized by altered striatal dopaminergic signalling that leads to motor and cognitive deficits. Parkinson's disease is also characterized by abnormal presence of soluble toxic forms of α-synuclein that, when clustered into Lewy bodies, represents one of the pathological hallmarks of the disease. However, α-synuclein oligomers might also directly affect synaptic transmission and plasticity in Parkinson's disease models. Accordingly, by combining electrophysiological, optogenetic, immunofluorescence, molecular and behavioural analyses, here we report that α-synuclein reduces N-methyl-d-aspartate (NMDA) receptor-mediated synaptic currents and impairs corticostriatal long-term potentiation of striatal spiny projection neurons, of both direct (D1-positive) and indirect (putative D2-positive) pathways. Intrastriatal injections of α-synuclein produce deficits in visuospatial learning associated with reduced function of GluN2A NMDA receptor subunit indicating that this protein selectively targets this subunit both in vitro and ex vivo. Interestingly, this effect is observed in spiny projection neurons activated by optical stimulation of either cortical or thalamic glutamatergic afferents. We also found that treatment of striatal slices with antibodies targeting α-synuclein prevents the α-synuclein-induced loss of long-term potentiation and the reduced synaptic localization of GluN2A NMDA receptor subunit suggesting that this strategy might counteract synaptic dysfunction occurring in Parkinson's disease.

Verified
Journal Article
Open access
PDF file
ACAntonella Cardinale
Antonella Cardinale
VCValeria Calabrese
Valeria Calabrese
AIAntonio de iure
Antonio de iure
Barbara PicconiBarbara Picconi
Barbara Picconi
Parkinson’s disease (PD) is considered the most common disorder of synucleinopathy, which is characterised by intracellular inclusions of aggregated and misfolded α-synuclein (α-syn) protein in various brain regions, and the loss of dopaminergic neurons. During the early prodromal phase of PD, synaptic alterations happen before cell death, which is linked to the synaptic accumulation of toxic α-syn specifically in the presynaptic terminals, affecting neurotransmitter release. The oligomers and protofibrils of α-syn are the most toxic species, and their overexpression impairs the distribution and activation of synaptic proteins, such as the SNARE complex, preventing neurotransmitter exocytosis and neuronal synaptic communication. In the last few years, the role of the immune system in PD has been increasingly considered. Microglial and astrocyte activation, the gene expression of proinflammatory factors, and the infiltration of immune cells from the periphery to the central nervous system (CNS) represent the main features of the inflammatory response. One of the actors of these processes is α-syn accumulation. In light of this, here, we provide a systematic review of PD-related α-syn and inflammation inter-players.

14 October 2019 in Nature Communications
Verified
Journal Article
Open access
PDF file
PKParaskevi Krashia
Paraskevi Krashia
ACAlberto Cordella
Alberto Cordella
ANAnnalisa Nobili
Annalisa Nobili
LBLivia La Barbera
Livia La Barbera
MFMauro Federici
Mauro Federici
Nicola Biagio MercuriNicola Biagio Mercuri
Nicola Biagio Mercuri
An amendment to this paper has been published and can be accessed via a link at the top of the paper.

31 March 2018 in Neuropharmacology
Verified
Journal Article
Closed access
PMPetra Mazzocchetti
Petra Mazzocchetti
MTMichela Tantucci
Michela Tantucci
GBGuendalina Bastioli
Guendalina Bastioli
VCValeria Calabrese
Valeria Calabrese
MFMassimiliano Di Filippo
Massimiliano Di Filippo
CCCinzia Costa
Cinzia Costa